{"id":"calcipotriene-clobetasol-propionate","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Burning or stinging at application site"},{"rate":null,"effect":"Folliculitis"},{"rate":null,"effect":"Hypercalcemia (with systemic absorption)"}]},"_chembl":null,"_dailymed":{"setId":"8957fab8-eca0-2494-e053-2995a90a6c29","title":"CALCIPOTRIENE 0.005% / CLOBETASOL PROPIONATE 0.05% SOLUTION [SINCERUS FLORIDA, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Calcipotriene binds to vitamin D receptors on keratinocytes and immune cells, promoting normal differentiation and reducing hyperproliferation characteristic of psoriasis. Clobetasol propionate, a Class I (super-potent) topical corticosteroid, activates glucocorticoid receptors to rapidly reduce inflammation, itching, and erythema. The combination provides synergistic anti-inflammatory and anti-proliferative effects for enhanced efficacy in psoriatic plaques.","oneSentence":"Calcipotriene is a vitamin D analog that regulates skin cell differentiation and proliferation, while clobetasol propionate is a potent corticosteroid that suppresses inflammation and immune response in the skin.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:43:08.710Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis"},{"name":"Psoriatic dermatitis"}]},"trialDetails":[{"nctId":"NCT01043224","phase":"PHASE1","title":"A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-01","conditions":"Psoriasis Vulgaris","enrollment":24},{"nctId":"NCT04220554","phase":"NA","title":"Improvement of Psoriasis Patients' Adherence to Topical Drugs","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2020-06-19","conditions":"Psoriasis Vulgaris","enrollment":103},{"nctId":"NCT00437255","phase":"PHASE4","title":"Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-08","conditions":"Plaque Psoriasis","enrollment":122},{"nctId":"NCT03758365","phase":"PHASE1","title":"Evaluation of the Vasoconstriction Properties of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-11-05","conditions":"Vasoconstriction","enrollment":36},{"nctId":"NCT03584360","phase":"PHASE2","title":"Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2018-09-24","conditions":"Psoriasis Vulgaris","enrollment":30},{"nctId":"NCT02680717","phase":"PHASE1","title":"Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2016-03","conditions":"Scleroderma","enrollment":""},{"nctId":"NCT03399526","phase":"PHASE1","title":"1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-02-11","conditions":"Psoriasis","enrollment":24},{"nctId":"NCT02973776","phase":"PHASE1","title":"Vasoconstriction Trial With LEO 90100 Aerosol Foam","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-12","conditions":"Psoriasis Vulgaris","enrollment":36},{"nctId":"NCT02940002","phase":"PHASE1","title":"BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-10-12","conditions":"Psoriasis","enrollment":23},{"nctId":"NCT01313221","phase":"PHASE3","title":"Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-04","conditions":"Psoriasis","enrollment":310},{"nctId":"NCT01745133","phase":"PHASE4","title":"Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"Leon Kircik, M.D.","startDate":"2013-01","conditions":"Psoriasis","enrollment":63},{"nctId":"NCT02733874","phase":"PHASE4","title":"A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris.","status":"COMPLETED","sponsor":"First Hospital of China Medical University","startDate":"2015-04","conditions":"Psoriasis","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sorilux foam + Olux E foam"],"phase":"marketed","status":"active","brandName":"calcipotriene + clobetasol propionate","genericName":"calcipotriene + clobetasol propionate","companyName":"Leon Kircik, M.D.","companyId":"leon-kircik-m-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Calcipotriene is a vitamin D analog that regulates skin cell differentiation and proliferation, while clobetasol propionate is a potent corticosteroid that suppresses inflammation and immune response in the skin. Used for Plaque psoriasis, Psoriatic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}